Skip to main content
Premium Trial:

Request an Annual Quote

CIDR to Use Illumina Tech in Diabetes Research; Center Could Adapt Tech as Standard

NEW YORK, Jan. 11 (GenomeWeb News) - The Center for Inherited Disease Research will use Illumina's Sentrix HumanHap300 BeadChip and Infinium Assay for a pilot study of Type 2 diabetes, the company said today.

According to Illumina, one goal of the research is to evaluate its technology for possible adoption as the standard platform for CIDR's genome-wide association service, which is expected to launch in the spring.

Terms of the alliance call for CIDR to use the Sentrix HumanHap300 BeadChip to query more than 317,000 tagSNPs on a single microarray device. Specifically, CIDR is working with Illumina to genotype more than 2,500 case-control samples provided by the Finland-United States Investigation of NIDDM Genetics Study. Funded by the National Institutes of Health, the goal of the FUSION team is to map and identify genetic variants that predispose individuals to Type 2 diabetes.

Financial terms of the alliance were not disclosed.

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.